DYNAMICS OF BRAIN NATRIURETIC PEPTIDE NT-pro-BNP LEVELS IN RESPONSE TO INTRAVENOUS ADMINISTRATION OF SOLUTIONS IN PATIENTS WITH ACUTE STROKE
DOI:
https://doi.org/10.11603/2414-4533.2024.3.14839Keywords:
infusion therapy, acute stroke, natriuretic peptideAbstract
The aim of the work: to establish a correlation between the levels of natriuretic peptide, their dynamics and the type of infusion solution in patients with acute cerebral stroke.
Materials and Methods. Patients with acute stroke were selected and divided into two groups. Selection criteria included the development of acute ischemic stroke within 6 to 24 hours, a level of consciousness of 10 or more scores on the Glasgow Coma Scale, and the absence of decompensated chronic heart failure, acute coronary events, or neurogenic pulmonary edema. Patients were randomized to groups and each patient's natriuretic peptide level was determined within the first hour of admission. Patients in the first group then received a 0.9 % sodium chloride solution bolus of 400 ml over 60 minutes, and patients in the second group received a 6 % HES 200/0.5 solution of 400 ml over 60 minutes. After the bolus, natriuretic peptide levels were reassessed. Statistical data processing was performed using formulas from Windows 11 Microsoft Office Excel, calculating means, standard deviations, and comparing group results with Student's t-test and p-value calculation. NT-pro-BNP levels were determined by an immunofluorescence method using Exdia Precision Biosensor Inc. test systems, Republic of Korea.
Results. In this research, no significant change in natriuretic peptide concentrations could be demonstrated in the patient groups receiving bolus administration of 0.9 % sodium chloride solution and 6 % HES solution, both within patient groups (1101.70±668.27 pg/ml and 1284.35±995.02 pg/ml with p ≥ 0.05 (0.29) for 0.9 % sodium chloride and 2219.198±1733.56 pg/ml and 2336.403±1629.98 pg/ml with p ≥ 0.05 (0.73) for 6 % HES solution) and in the between-group analysis (1284.35±995.02 pg/ml for 0.9 % sodium chloride and 2336.40±1629.98 pg/ml for 6 % HES solution with p ≥ 0.05 (0.088) at 60 minutes).
References
Aimo A, Januzzi JL Jr, Vergaro G, Ripoli A, Latini R, Masson S, Magno li M, Anand IS, Cohn JN, Tavazzi L, Tognoni G, Gravning J, Ueland T, Nymo SH, Rocca HB, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Wilson Tang WH, Grodin JL, Passino C, Emdin M. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology. 2019;277:166-172. DOI: 10.1016/j.ijcard.2018.10.079 6.
Diaz-Arocutipa C, Saucedo-Chinchay J, Imazio M, Argulian E. Natriuretic peptides to differentiate constrictive pericarditis and restrictive cardiomyopathy: A systematic review and meta-analysis. Clin Cardiol. 2022;45:251–257. DOI: 10.1002/clc.23772.
Erbay AR, Yilmaz MB, Balci M, Sabah I. Atrial natriuretic peptide levels in adult patients before and after surgery for correction of atrial septal defects: relationship with atrial arrhythmias. Clinical Science. 2004;107(3):297-302. DOI: 10.1042/CS20040141 13.
Llitjos JF, Carrol ED, Osuchowski MF, Bonneville M, Scicluna, Didier Payen BP, Randolph AG, Witte S, Manzano JR, François B, and on behalf of the Sepsis biomarker workshop group. Enhancing sepsis biomarker development: key considerations from public and private perspectives. Critical Care. 2024; 28:238. DOI: 10.1186/s13054-024-05032-9.
Kanwar MK, Blumer V, Zhang Y, Sinha SS, Garan AR, Hernandez-Montfort J, Khalif A, Hickey GW, Abraham J, Mahr C, Li B, Sangal P, Walec KD, Zazzali P, Kataria R, Pahuja M, Ton VK, Harwani NM, Wencker D, Nathan S, Vorovich E, Hall S, Khalife W, Li S, Schwartzman A, Kim JU, Vishnevsky OA, Trinquart L, Burkhoff D, Kapur NK. Pulmonary Artery Catheter Use and Risk of In-hospital Death in Heart Failure Cardiogenic Shock. J Card Fail. 2023 Sep;29(9):1234-1244. DOI: 10.1016/j.cardfail.2023.05.001.
Koji Takagi, Antoine Kimmoun, Naoki Sato, and Alexandre Mebazaa. Management of Acute Heart Failure during an Early Phase. Int J Heart Fail. 2020 Apr;2(2):91-110. DOI: 10.36628/ijhf.2019.0014.
Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40(3):303-309. DOI: 10.1007/s15010-011-0235-0.
Morfino P, Aimo A, Castiglione V, Vergaro G, Emdin M, Clerico A. Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. J. Cardiovasc. Dev. Dis. 2022; 9:256. DOI: 10.3390/jcdd9080256.
Pandompatam G, Kashani K, Vallabhajosyula S. The role of natriuretic peptides in the management, outcomes and prognosis of sepsis and septic shock. Rev Bras Ter Intensiva. 2019;31(3):368-378.
Hernández RM, Rueda FR. Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence. J. Pers. Med. 2023; 13:333. DOI: 10.3390/jpm13020333.
Saarwaani Vallabhajosyula, Zhen Wang, M. Hassan Murad, Shashaank Vallabhajosyula, Pranathi R. Sundaragiri, Kianoush Kashani, Wayne L. Miller, Allan S. Jaffe and Saraschandra Vallabhajosyula. Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis. Mayo Clin Proc Inn Qual Out. 2020;4(1):50-64 DOI: 10.1016/j.mayocpiqo.2019.10.008
Tokudome T, Otani K. Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide. Biology. 2022; 11:1351. DOI: 10.3390/biology11091351.
Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews. 2022; 27:625–643 DOI: 10.1007/s10741-021-10105-w.
Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, Januzzi JL, Maisel AS, McDonald K, Mueller T, Richards AM, Seferovic P, Mueller C, de Boer RA. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA). European Society of Cardiology (ESC) European Journal of Heart Failure. 2021; 23:1610–1632. DOI: 10.1002/ejhf.2346.
Sheng X, Yang J, Yu G, Fei Y, Bao H, Yin J, Huang W, Tian Z, Wang N, Ronco C. Natriuretic Peptide for Prognosis in Septic Acute Kidney Injury Patients Receiving Renal Replacement Therapy. Blood Purif. 2019; 48(3): 262–271. DOI: 10.1159/000501388.
Nakagawaa Y, Nishikimia T, Kuwaharac K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019; 111: 18–25.
Zhao YH, Gao H, Pan ZY, Li J, Huang WH, Wang ZF, Li ZQ. Prognostic Value of NT-proBNP After Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Journal of Stroke and Cerebrovascular Diseases. 2020; 29(4):104659. DOI: j.jstrokecerebrovasdis.2020.104659.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 А. І. СУХОДОЛЯ, К. Ю. КРЕНЬОВ, І. В. ЛОБОДА
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
